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May 1, 2012:1658–61This also suggests that peripheral components such as muscle
function had a share in the improvement seen in the interven-
tion group (5). After all, it is not yet clear whether exercise
training can induce an improvement in ventilatory efficiency in
HFpEF. A larger, prospective, randomized controlled trial that
is now underway (6) will contribute to clarification of this issue.
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Prevalence of J-Point Elevation
in Families With Sudden
Arrhythmic Death Syndrome
We congratulate Nunn et al. (1) for their interesting report
published recently in the Journal. They reported that J-point
elevation in the inferolateral leads was more prevalent in the
first-degree relatives of patients with sudden arrhythmic death
syndrome (SADS) than in controls. They suggested that early
repolarization was a potentially heritable proarrhythmic marker,
risk modifier for lethal arrhythmia, or marker of proarrhythmiain SADS (1). Because J-point elevation is highly prevalent in
the healthy population, the report by Nunn et al. (1) encourages
the development of better clinical algorithms. Because this
study was confined to the relatives of patients with SADS, the
significance of J-point elevation found in clinically healthy
individuals (electrocardiogram obtained for pre-operative clear-
ance, sports suitability, or job-related check) in the absence of a
family history of SADS would probably be minimal. Should it
be important to obtain family history in individuals showing
J-point elevation? The researchers highlighted that a gene
association study or linkage analysis to identify genetic candi-
dates is a logical next step. Although waiting for the availability
of more extensive knowledge on the genetic basis of J-point
elevation, the risk of missing a potential warning marker would
continue to loom in clinical practice.
The group of J-wave syndromes is a spectrum of disorders that
involve accentuation of the epicardial action potential notch in
different regions of the heart that may predispose patients to
develop phase 2 reentry and ventricular tachyarrhythmias. J-point
elevation has been divided into 3 subtypes (2,3). An early repolar-
ization pattern in the lateral precordial leads is rarely seen in
survivors of ventricular fibrillation (VF) (type 1). On the other
hand, J-point changes in inferior or inferolateral leads are usually
associated with many cases of idiopathic VF (type 2), and global
early repolarization patterns are associated with the highest risk
for development of malignant arrhythmias, including VF storms
(type 3).
We have observed J-point elevations in young carriers of
mutations of various genes (including lamin A/C and plakophilin
2), as well as in healthy relatives of patients with mutation (Fig. 1).
After the publication of Nunn et al. (1), this finding cannot be
ignored, and it will be important to develop a consensus for the
approach to healthy individuals with J-point elevation with and
without a family history of SADS.
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We thank Dr. Serio and colleagues for their interest in our paper
(1) and for their letter highlighting the clinical challenge of
asymptomatic early repolarization (ER). We noted the examples of
J-point elevation in a healthy individual, 2 patients with genetic
forms of cardiomyopathy, and a mutation-negative relative. These
cases are entirely consistent with our hypothesis that ER may be an
independent clinical trait that increases arrhythmic risk in genet-
ically predisposed individuals, but they also illustrate the impor-
tance of context when deciding on the clinical significance of ER.
The fundamental clinical distinction is that between physiological
J-point elevation, which conveys little or no arrhythmic risk to an
individual, and a pathological ER phenomenon that predisposes
patients to ventricular fibrillation (VF). In population studies, the
presence of a J wave increases the risk of idiopathic VF from 3.4 per
100,000 to 11 per 100,000, making the odds that an individual has a fatal
Figure 1 Different Patterns of J-Point Elevation in Normal indivi
DCM  dilated cardiomyopathy; HCM  hypertrophic cardiomyopathy.disease 1:10,000, which is too small to influence management (2). sA variety of associated electrocardiogram (ECG) parameters
uch as the location and amplitude of J-point elevation and a shorter
T interval have been suggested as indicators of an increased risk of
F. However, data from large population cohorts have indicated that
he risk is greater in older patients with left ventricular hypertrophy
nd ischemic heart disease (3,4). These findings need confirmation in
arger independent cohorts, and they indicate that other ECG
nomalies may be important in determining the sudden death risk of
he individual. In addition, further refinement and elucidation of the
attern of ER is still merited.
Based upon our observations and current understanding of the
ole of ER in VF mechanisms, we suggest that a family history of
udden arrhythmic death syndrome (SADS), epilepsy, or unex-
lained syncope are new considerations in the interpretation of ER
n an ECG because these may indicate either pathological ER or
R in the context of a separate proarrhythmic condition.
In conclusion, at present, ER in the absence of symptoms,
tructural heart disease, or family history of SADS should not be
and in Patients With HCM and DCMdualseen as a major independent risk factor for sudden death. In patients
